文献速递神经肿瘤

动态18F-FET PET是钆增强阴性胶质瘤中有力的影像学生物标志物

Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas.
PubMed 文献 · Neuro Oncol · 2019-01-01

该研究纳入98例钆增强阴性胶质瘤患者,在18F-FET PET引导下活检,对肿瘤时间-放射性曲线(TAC)定性分类为递增型、混合型和递减型,并进行TTPmin定量分析。结果显示三组调整后5年生存率分别为85%、47%和19%(P<0.001),影像模型与生物标本模型预测效能相似,TAC测量是独立于肿瘤分级和IDH状态的生物标志物。

要点

  • 钆增强阴性胶质瘤中,递增型、混合型和递减型TAC的调整后5年生存率分别为85%、47%和19%(P<0.001)。
  • TTPmin在递增型TAC组最长、递减型TAC组最短,混合型TAC组居中,且IDH突变肿瘤TTPmin更长(P<0.001)。
  • 影像模型与生物标本模型对生存的预测精度相似,TAC测量独立于肿瘤分级和IDH状态。

核心结论

  • TAC测量构成独立于肿瘤分级和IDH状态的有力生物标志物。

研究设计与样本

  • 研究纳入98例钆增强阴性胶质瘤患者,均接受18F-FET PET引导活检,对每个肿瘤的TAC进行定性分类为递增型或递减型,并事后进行TTPmin定量分析,采用多因素风险模型获取预后因素并比较生物标本模型与影像模型的拟合度。

主要发现

  • 均匀递增型、混合型和均匀递减型TAC分别见于51、19和28个肿瘤。
  • 三组调整后5年生存率分别为85%、47%和19%(P<0.001)。
  • 定性与定量TAC测量高度相关(P<0.0001)。
  • TTPmin在均匀递增型TAC组最长、均匀递减型TAC组最短,混合型TAC组居中;IDH突变肿瘤TTPmin更长(P<0.001)。
  • 生物标本模型与影像模型对结局的预测精度相似;在生物标本模型中,WHO分级(P<0.0001)和IDH状态(P<0.001)是生存预测因素。

关键数值与推荐

  • 均匀递增型TAC肿瘤的结局与TTPmin>25分钟肿瘤及IDH突变型II级胶质瘤几乎一致,均匀递减型TAC肿瘤的结局与TTPmin≤12.5分钟肿瘤及IDH野生型胶质瘤几乎一致。
  • 混合型TAC肿瘤的结局与中间TTPmin(>12.5分钟且≤25分钟)肿瘤及IDH突变型III级胶质瘤一致。
  • 三个预后聚类在各自模型中均与其他聚类显著不同(P<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to elucidate the place of dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) PET in prognostic models of gadolinium (Gd)-negative gliomas. METHODS: In 98 patients with Gd-negative gliomas undergoing 18F-FET PET guided biopsy, time activity curves (TACs) of each tumor were qualitatively categorized as either increasing or decreasing. Additionally, post-hoc quantitative analyses were done using minimal time-to-peak (TTPmin) measurements. Prognostic factors were obtained from multivariate hazards models. The fit of the biospecimen- and imaging-derived models was compared. RESULTS: A homogeneous increasing, mixed, and homogeneous decreasing TAC pattern was seen in 51, 19, and 28 tumors, respectively. Mixed TAC tumors exhibited both increasing and decreasing TACs. Corresponding adjusted 5-year survival was 85%, 47%, and 19%, respectively (P < 0.001). Qualitative and quantitative TAC measurements were highly intercorrelated (P < 0.0001). TTPmin was longest (shortest) in the homogeneous increasing (decreasing) TAC group and in between in the mixed TAC group. TTPmin was longer in isocitrate dehydrogenase (IDH)-mutant tumors (P < 0.001). Outcome was similarly precisely predicted by biospecimen- and imaging-derived models. In the biospecimen model, World Health Organization (WHO) grade (P < 0.0001) and IDH status (P < 0.001) were predictors for survival. Outcome of homogeneous increasing (homogeneous decreasing) TAC tumors was nearly identical, with both TTPmin > 25 min (TTPmin ≤ 12.5 min) tumors and IDH-mutant grade II (IDH-wildtype) gliomas. Outcome of mixed TAC tumors matched that of both intermediate TTPmin (>12.5 min and ≤25 min) and IDH-mutant, grade III gliomas. Each of the 3 prognostic clusters differed significantly from the other ones of the respective models (P < 0.001). CONCLUSION: TAC measurements constitute a powerful biomarker independent from tumor grade and IDH status.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Kunz M, Albert NL, Unterrainer M, et al. Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas. Neuro Oncol. 2019. PMID: 29893965. doi:10.1093/neuonc/noy098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。